To address changes in the policy and operational environment of the pharmaceutical industry, as well as to implement the development requirements put forward by the Ministry of Industry and Information Technology,2019Huaren Shuanghe has formulated the 'Huaren Shuanghe's 14th Five-Year Product Development Strategy', aiming to complete the company's strategic transformation towards innovation and realize the vision of 'becoming a world-class pharmaceutical enterprise trusted by the public and driven by innovation'.
7month4Today, Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the Mid-Term Planning Seminar for China Resources Shuanghe's 14th Five-Year Plan. He also presented a report on the extension development consulting report for the mid-term strategic review of China Resources Shuanghe's 14th Five-Year Plan, contributing to the strategic transformation of Shuanghe.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Under the guidance of the principles of leading-edge, similarity and scientificity, the Frost & Sullivan healthcare team has selected top global pharmaceutical companies and leading domestic pharmaceutical companies for benchmarking analysis. Through benchmark analysis, it can be found that domestic and international pharmaceutical companies have all gone through different stages of development from scale expansion to innovation transformation, with external expansion always being an important means for achieving strategic goals at different stages.
Mao Hua stated that, in light of the company's current situation and benchmarking insights, China Resources Shuanghe should take measures to continuously enhance its project sourcing capabilities, improve organizational structure, and optimize collaboration mechanisms.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and the cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
2023Frost & Sullivan's New Investment Conference
